These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9557744)

  • 41. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice.
    Inn KS; Lee GJ; Quan FS
    Immunol Invest; 2014; 43(3):236-54. PubMed ID: 24354853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
    Johansson BE
    Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
    Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
    Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing.
    Donis RO; ; Davis CT; Foust A; Hossain MJ; Johnson A; Klimov A; Loughlin R; Xu X; Tsai T; Blayer S; Trusheim H; Colegate T; Fox J; Taylor B; Hussain A; Barr I; Baas C; Louwerens J; Geuns E; Lee MS; Venhuizen O; Neumeier E; Ziegler T
    Vaccine; 2014 Nov; 32(48):6583-90. PubMed ID: 24975811
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells.
    Govorkova EA; Matrosovich MN; Tuzikov AB; Bovin NV; Gerdil C; Fanget B; Webster RG
    Virology; 1999 Sep; 262(1):31-8. PubMed ID: 10489338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses.
    Meyer WJ; Wood JM; Major D; Robertson JS; Webster RG; Katz JM
    Virology; 1993 Sep; 196(1):130-7. PubMed ID: 8356790
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus.
    Lee KH; Seo SU; Song JM; Lee CM; Kim HA; Seong BL
    Vaccine; 2006 Mar; 24(11):1966-74. PubMed ID: 16343703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture.
    Halperin SA; Nestruck AC; Eastwood BJ
    Vaccine; 1998 Aug; 16(13):1331-5. PubMed ID: 9682398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
    Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
    Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition.
    Oxford JS; Newman R; Corcoran T; Bootman J; Major D; Yates P; Robertson J; Schild GC
    J Gen Virol; 1991 Jan; 72 ( Pt 1)():185-9. PubMed ID: 1990062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
    Lee YH; Jang YH; Seong BL
    Virology; 2017 Apr; 504():73-78. PubMed ID: 28157547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
    Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of high-yield influenza B virus vaccine viruses.
    Ping J; Lopes TJ; Neumann G; Kawaoka Y
    Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8296-E8305. PubMed ID: 27930325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.
    Swayne DE; Suarez DL; Spackman E; Jadhao S; Dauphin G; Kim-Torchetti M; McGrane J; Weaver J; Daniels P; Wong F; Selleck P; Wiyono A; Indriani R; Yupiana Y; Sawitri Siregar E; Prajitno T; Smith D; Fouchier R
    J Virol; 2015 Apr; 89(7):3746-62. PubMed ID: 25609805
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
    Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.